EDX Medical Group Plc

Report Publication Announcement • Sep 1, 2025

National Storage Mechanism | Additional information

RNS Number : 2984X

EDX Medical Group PLC

01 September 2025

1 September 2025

EDX Medical Group   plc  ·  EDX

AQSE: EDX

("EDX Medical" or the "Company")

Posting of Notice of AGM and Annual Report

CAMBRIDGE, UK:  EDX Medical Group Plc (AQSE: EDX) ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces that its annual general meeting ("AGM") will be held at the Marcus Beck Library, 3rd Floor, Royal School of Medicine, 1 Wimpole Street, Westminster, London, W1G 0AE on 29 September 2025 at 2:00 p.m.

The annual report and financial statements for the year ended 31 March 2025, Notice of AGM and Form of Proxy will be posted today, 1 September 2025, to eligible shareholders. Electronic copies will be shortly available on the Company's website at: https://edxmedical.co.uk/documents/

ENDS

Contacts:

EDX Medical Group plc
Dr Mike Hudson  (Chief Executive Officer)	+44 (0)7812 345 301
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	+44 (0)20 3179 5300
Media House International
Ramsay Smith Gary McQueen	+44 (0)7788 414856 [email protected] +44 (0)7834 694609 [email protected]
IFC Advisory (Investor Relations)
Tim Metcalfe Graham Herring	+44 (0) 203 934 6630

Notes to Editors:

About EDX Medical Group plc

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXEADPNAALSEFA